May 04, 2011 -- LinkMed transplantation company Olerup SSP has signed an exclusive five-year global
marketing, sales and distribution agreement with the Australian company Conexio for
Conexio’s SBT Resolver™- HLA Sequencing Based Typing product line and sequence
analysis software. Olerup SSP will now be able to broaden its product offer towards the
Conexio’s SBT Resolver™ products are locus specific PCR based HLA sequencing based typing
(SBT) reagents. The agreement includes SBT kits and a version of Assign™ sequence analysis
software. The SBT product line will be a strong complement to the HLA typing technology
developed by Olerup SSP® and sold through its sales channels Olerup Inc., Olerup GmbH and
Olerup SSP and Conexio have also agreed to co-develop new HLA typing products.
Olerup SSP and Conexio will jointly promote the products at the 25th EFI (European
Immunogenetics and Histocompatibility) conference in Prague, Czech Republic, May 4–7, 2011.
“This is a big step for us and we expect the collaboration with Conexio to broaden and strengthen
our position on the global HLA typing market with a very competitive SBT solution that
complements our current product portfolio. It is also a proof that we, in a very short period of time,
have been able to build a global organization that can handle distribution and sales for new
innovative products towards the transplantation market. The potential for SBT is at least as big as
our SSP business”, says Dr. Olle Olerup, CEO Olerup SSP.
”We looked at several different options for our SBT Resolver™ product line and sequence
analysis software and felt that collaboration with Olerup SSP would enable us to best provide
high quality solutions to HLA typing laboratories. We are now looking forward to a long and
healthy collaboration with Olerup SSP”, says Dr David Sayer, CEO and co-founder of Conexio.
Conexio is a Western Australian company that specializes in the development of sequencing
technology for HLA typing and mutation detection. Currently over 100 research and hospital
laboratories throughout the world use Conexio’s sequence analysis software Assign™ and SBT
reagents sold under license through other companies. The Assign™ software and SBT
Resolver™ reagents facilitate high throughput DNA sequencing as an accurate method for HLA
For more information please contact:
Olle Olerup, CEO Olerup SSP, phone: +46 (0)70-317 90 98 or email:email@example.com.
Or visit www.olerup.com or www.linkmed.se
LinkMed AB discloses the information provided herein pursuant to the Securities Markets Act
and/or the Financial Instruments Trading Act. The information was submitted for publication at
13:00 (CET) on May 4, 2011.
LinkMed develops life science companies in collaboration with innovators and other financiers. By
contributing management and capital, LinkMed has created a portfolio of thirteen companies, four
in drug development and biotechnology and nine in diagnostics and medical technology. The
company’s principal shareholders are Mohammed Al Amoudi, FastPartner AB (publ), and
Mannersons Fastighets AB. LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the
Small Cap section (ticker: LMED).